Regulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround

AnalystLowTarget

Not Invested

Community Contributor

Published

20 Apr 25

Updated

07 May 25

AnalystLowTarget's Fair Value

US$100.00

6.0% undervalued

10 Sep

US$94.05

-23.2%

11.7%

-23.2%

11.7%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$1006.0% undervalued

AnalystLowTarget Fair Value

Narrative

Updates3

Shared on07 May 25

Shared on30 Apr 25

Shared on23 Apr 25

AnalystLowTarget Fair Value

US$100

6.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.13%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.90%

Calculation

US$411.30m

Earnings '28

30.52x

PE Ratio '28

US$12.55b

Market Cap '28

US$12.55b

Market Cap '28

100.70m

No. shares '28

US$124.67

Share Price '28

US$124.67 Share Price '28

Discounted to 2025 @ 7.88% p.a.

US$99.31

Fair Value '25